Sanford-Burnham
Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program From Salk Institute, Sanford Burnham Prebys
The company plans to begin clinical studies of ENV-201 in lung and colorectal cancers with LKB1 mutations within the next 18 months.
The company plans to begin clinical studies of ENV-201 in lung and colorectal cancers with LKB1 mutations within the next 18 months.